Next generation sequencing has become a powerful tool in dissecting and identifying mutations and genomic structural variants that accompany tumourigenesis. Sequence analysis of glioblastoma multiforme (GBM) illustrates the ability to rapidly identify mutations that may affect phenotype. Approximately 50% of human GBMs overexpress epidermal growth factor receptor (EGFR) which renders the EGFR protein a compelling therapeutic target. In brain tumours, attempts to target EGFR as a cancer therapeutic, however, have achieved little or no benefit. The mechanisms that drive therapeutic resistance to EGFR inhibitors in brain tumours are not well defined, and drug resistance contributes to the deadly and aggressive nature of the disease. Whole genome sequencing of four primary GBMs revealed multiple pathways by which EGFR protein abundance becomes deregulated in these tumours and will guide the development of new strategies for treating EGFR overexpressing tumours. Each of the four tumours displayed a different mechanism leading to increased EGFR protein levels. One mechanism is mediated by gene amplification and tandem duplication of the kinase domain. A second involves an intragenic deletion that generates a constitutively active form of the protein. A third combines the loss of a gene which encodes a protein that regulates EGFR abundance as well as an miRNA that modulates EGFR expression. A fourth mechanism entails loss of an ubiquitin ligase docking site in the C-terminal part of the protein whose absence inhibits turnover of the receptor.
Introduction
The advent of next generation sequencing (NGS) along with continued reduction of sequencing costs has opened new opportunities for detecting mutations and structural genomic variants and their associations with disease. In this study, four glioblastoma multiformes (GBMs), the most common and aggressive form of primary brain tumour in adults (1) , were subjected to whole genome sequencing. A common goal in the study and treatment of patients with GBM, which has a median survival of about 1 year to 15 months (1,2), has been to identify and understand signature gene expression patterns and pathways to enable better and more reliable predictive and therapeutic strategies. The Cancer Genome Atlas project (TCGA), a consortial tumour data repository with gene expression data for several hundred GBMs, partially fulfils this purpose and provides a foundation for molecular profiling (3) . These and other independently derived data have laid the basis for molecular stratification of GBM subtypes with individualised treatment of glioblastoma patients being an ultimate goal (4) (5) (6) (7) (8) .
Among genes most commonly, but not exclusively affected by substitution, deletion, amplification, overexpression or genomic rearrangement in GBMs are PTEN, PDGFRA, TP53, CDKN2A, NF1, IDH1, MDM2 and EGFR (4) (5) (6) (7) (8) (9) (10) . Recently, a large genomics study undertaken by TCGA has published findings on a large database of GBM sequences that definitively supports much of what has been known in addition to adding supporting data highlighting the role of gene fusions and the deletion of the apoptosis regulator gene FAF1 (11) . Additionally, Frattini et al. (12) further described the role of gene fusions in GBM, further supporting the idea that these recombinatory events that result in malignancy play a significant role in the development of GBM.
While several of the receptor tyrosine kinase genes are aberrantly expressed in GBMs, the most commonly affected is that encoding the epidermal growth factor receptor (EGFR), the prototypical member of the ErbB family of receptors (13) . Amplification of DNA harbouring EGFR in GBMs, as well as EGFR protein overexpression, has been known for a quarter of a century (14, 15) and is manifest in 30-50% of all primary GBMs (16) (17) (18) . Whether or not EGFR overexpression is associated with clinical outcome is unclear (19) . Some reports indicate that poor survival is associated with EGFR overexpression (18, 20) , but mainly when p53 is wild type (21) . Another study reported that alteration of both EGFR and p53 results in a poor prognosis (22) . Similarly, poor outcome is reported to be a function of age (17, 23) . Conversely, there are several reports indicating that EGFR amplification has little, if any, predictive value (1, 24, 25) and that in some subgroups overexpression might be associated with prolonged survival (26) . Although elevated EGFR levels have been associated with oncogenesis, additional oncogenic events are likely required for malignancy. Loss of the phosphatase and tensin homolog (PTEN) tumour suppressor, for example, often accompanies EGFR amplification (27) but primarily in combination with other oncogenic events such as expression of cSrc (28) , and constitutively activated signal transducer and activator of transcription 3 (STAT3), (29) or loss of cyclin-dependent kinase inhibitor 2A (CDKN2A) (7, 16, (30) (31) (32) (33) .
In this study, we leverage the power of NGS to better understand the different mechanisms involved in the deregulation of EGFR protein in several GBM tumours. While some of these mechanisms have been described previously, the use of whole genome sequencing and our ability to detect structural variants and copy number increases in relatively low-coverage sequences directly from clinical samples demonstrates the power of this analysis in identifying global genomic alterations in pathways associated with EGFR pathway deregulation. Sequence analysis has shown that each of the four GBMs manifests a different genomic mechanism that results in elevated EGFR levels. This analysis also helped us to develop new rational hypotheses for potential targeted therapies. Similar studies will pave the way for the routine use of NGS as part of the clinical management of patients with brain tumours.
Materials and methods

Ethics statement
Tumour tissue collection was approved by the Institutional Review Board (IRB# 11-12-02-06) and each patient was consented about the purpose of the experiment before collection.
Patient DNA isolation DNA extraction was carried out utilising Qiagen QIAamp DNA Microkit (Qiagen, Valenca, CA, USA) according to the manufacturer's protocol. Briefly, 180 μl of the tissue lysis buffer (buffer ATL) was added to 1-2 mm 3 slices of frozen or fresh tissues, mixed by pipetting and drawn into an eppendorf tube. Proteinase K (20 μl) was added to each tube and samples were incubated overnight at 56°C. The remainder of the DNA extraction was in accordance to the manufacturer's provided protocol.
For normal DNA extraction from the white blood cells (WBCs), blood samples were centrifuged for 15 min at 2000×g and the interface layer was transferred to a 1.7 ml microcentrifuge tube. The WBCs were centrifuged again at 2000×g and contaminating red blood cells (RBCs) were removed from the bottom of the tube. Remaining WBCs and RBCs were resuspended in 4 ml of RBC lysing buffer (Sigma #R7757) and left at room temperature for 15 min. WBC suspension was centrifuged at 2000×g for 10 min. The supernatant was aspirated and discarded. WBCs were washed with 1× phosphate buffered saline (PBS) and centrifuged at 2000×g for 3 min. PBS was aspirated off and WBC pellet was frozen at −80°C until DNA isolation using QIAamp DNA Blood Mini kit (Qiagen# 51104).
The DNA integrity and quality was assessed using minigel electrophoresis and the 260/280 absorbance ratio assessed with an Epoch spectrophotometer plate reader (Biotek, Winooski, VT, USA). Extracted DNA was stored at −20°C until the time of experiments.
Constructing paired end sequencing libraries and Illumina sequencing
Genomic DNAs (gDNAs) were extracted from frozen tumour samples and its isogenic control of patient-matched tumour-free WBCs using the DNeasy blood and tissue kit (Qiagen, Santa Clara, CA, USA). Library construction was performed according to a published protocol (34, 35) with few modifications. The input gDNAs were randomly fragmented by nebulisation generating 300-500 bp fragments followed by an end-blunting reaction catalysed by 15U T4 DNA polymerase, 5U Klenow DNA polymerase and 50U T4 polynucleotide kinase (PNK) (New England Biolab, Ipswich, MA, USA) in the presence of 1× PNK buffer, 1 mM ATP and 0.4 mM dNTP. Subsequently, an adenosine overhang (A-tail) was added onto the 3′-end of gDNA fragments catalysed by 15U Klenow-exo (New England Biolab) in the presence of 1× NEB buffer 2 and 2 mM dATP, followed by the first size selection (SS1) of gDNA fragments at the range of 475-525 bp on a 2% agarose gel (Bio-RAD, Hercules, CA, USA). The SS1-gDNAs fragments were ligated to Illumina paired-end (PE) adapters (35) on both ends. The PE adapters have a thymidine overhang (T-tail) on their 3′ end. The presence of A and T tails can facilitate ligation between SS1-gDNAs fragments and adapters whereas precluding gDNA self-ligation. After adapter ligation, a second size selection (SS2) was performed in order to remove chimeras, the ligation artifacts. Subsequently, a PCR reaction was performed to enrich the valid PE-tagged libraries. Approximately 10 ng of the SS2 product was used as input for 10 cycles of enrichment PCR with 2U of Platinum Pfx DNA polymerase (Invitrogen, Carlsbad, CA, USA), 1× Pfx buffer, 2 mM MgSO 4 , 400 µM dNTPs and 1 µM Illumina enrichment PCR primers (35) synthesised by IDT (IDT, Coralville, IA, USA). The PCR amplicons were purified, quantified by Qubit-iT dsDNA high sensivity assay kit (Invitrogen), validated by Agilent 2100 BioAnalyzer (Agilent, Santa Clara, CA, USA) and subjected to PE sequencing in an Illumina HiSeq 2500 platform using the SBS v3 sequencing kit (Illumina, San Diego, CA, USA). For each genome, ~350 millions of sequencing reads were collected, with a readout length of 100 bp for each read. In total, ~35 gigabases (Gb) of sequences were generated for each genome, with an average base coverage of ~10 fold of human haplotype reference genome (RefSeq), and an average mapping coverage of ~23.5 fold.
Data analysis
We have assembled a computational pipeline to analyse raw Illumina sequencing data. Our pipeline is tailored for the detection of somatic copy number aberrations (CNAs) as well as somatic structural variations: large (>200 bp) deletions, insertions, inversions and translocations. While single nucleotide polymorphisms and small insertions/deletions (indels) are detectable using the pipeline, this analysis was not included in our results.
Briefly, the raw sequencing data are first aligned to human hg19 RefSeq and converted to sequence alignment/map format with the Bowtie 2 Aligner (36). Picard-tools was then used to add RG headers with the AddOrReplaceReadGroups command. Files were then converted to binary sequence alignment/map format with Samtools view (37) , and sorted by chromosome and had their PCR duplicates marked with Picard-tools SortSam, and MarkDuplicates commands, respectively. Finally, these files underwent an indel realignment and base quality recalibration process using the Genome Analysis Tool Kit (38) .
CNA events were detected using Control-FREEC, which automatically computes, normalises and segments copy number profiles based on read depth ratio of our tumour-normal paired data and calls somatic copy number alterations and LOH (39) . While this analysis is not dependent on tumour-normal matched controls, some of our computationally detected CNA events, such as EGFR gene amplification and homozygous deletion of CDKN2A, have been validated by real time PCR.
Different types of somatic structural variations (SVs), including deletion (DEL), insertion (INS), inversion (INV), intra-chromosomal rearrangements (ITX) and inter-chromosomal translocation (CTX), were detected by the BreakDancer (40), using the parameters demanding a minimal MapQ = 30 and the presence of at least 5 non-redundant read pairs defining a SV event. Due to the high false-positive rate inherent to Breakdancer, somatic structural variant calls were confirmed through visualisation in using Integrative Genomics Viewer (IGV) (41) . In addition, several somatic ITX calls provided evidence for the existence of tandem duplications and/or double minutes.
Circos plots were generated in order to better visualise and establish correlations between SVs and copy number data. Circos diagrams allow for the organisation of data into various tracks aligned to corresponding locations in the genome arranged across a circular chromosomal spread (42) .
EGFR cDNA library construction and sequencing
For each patient, tumour cDNA libraries were created using 1 μg of patient RNA and the iScript cDNA kit (Biorad #170-8891). Primers were designed to produce four main overlapping EGFR fragments, ~1 kb in length. PfuTurbo DNA polymerase (0.5 μl) was added to improve accuracy and coverage (Agilent #600252). Additional primers were designed for better coverage of 5′ and 3′ ends of EGFR (set 1a and short set 4). Approximately 100 ng of cDNA was amplified in a 50 μl reaction containing 2× Taq Master Mix (Apex #42-132) and 0.1 μM of each primer. Fragments 1a, 1b, 2 and 3 also required 1 μl DMSO. After PCR, appropriate bands were excised from gels and purified using Qiagen gel extraction kit (#28704). Cleaned PCR products for each patient were sent to Cincinnati Children's Hospital DNA Core for Sanger sequencing from both 5′ and 3′ ends. Several of these sequencing reactions, including a deletion of CDKN2A in patient 1, a C7orf10 deletion in patient 3 and the translocations involved in the EGFRvIII mutation in patient 7 are being included in this report (Supplementary Figures S2-S4 , available at Mutagenesis Online). 
Immunohistochemistry
Patient tumour samples were fixed and paraffin-embedded after resection and sequentially
EGFR copy number variations
Copy number variation (CNV) assays were performed on Applied Biosystems 7200 StepOne Plus using CNV assays from ABI. Three probes for EGFR were selected in introns 1, 11 and 21 (ABI # Hs04960197_cn, Hs04991419_cn, and Hs04966836_cn) and were normalised to RNaseP (ABI #4403326) to assess EGFR CNV's in tumour versus WBC for each patient. Data analysis was performed using Stepone and Copycaller Software (ABI).
Availability of supporting data
Supporting data is available upon request by contacting El Mustapha Bahassi at bhassiem@uc.edu.
Results
EGFR levels are elevated and downstream pathways activated based on immunohistochemistry
As a part of a continuing effort to develop personalised biomarkers for monitoring GBM tumour dynamics in patients undergoing treatment, we sequenced the entire genome of 10 gliomblastomas and their corresponding constitutional WBC DNAs. Of the 10 tumours, 7 displayed varying levels of EGFR protein overexpression by IHC. Further genetic analysis showed that overexpression of EGFR in these tumours could be classified into four different subgroups. Four tumours representing each subgroup are described in this study. Using IHC, we investigated the level of EGFR and its relative activity based on the extent of phosphorylation of some of its downstream modulator proteins including p70S6-kinase (S6K), eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and Fork-head box O 3 (FOXO-3). As seen in Figure 1 , all four tumours displayed elevated levels of EGFR protein, with patients 1 and 8 expressing the highest levels and patients 3 and 7 expressing more moderate levels of the protein. However, phospho-S6-kinase (p-S6K) levels were high in all patients with patient 3 showing the highest activity. The very high abundance of phosphorylated S6K in patient 3 may be due to activation of the pathway through a parallel receptor such as PDGFRA. The levels of FOXO-3 and phosphorylated 4E-BP1 are likewise elevated indicating that the EGFR pathway is hyperactive in all patients regardless of how EGFR activation is mediated.
EGFR overexpression is mediated by amplification of the EGFR gene
In silico whole genome sequence analysis revealed that EGFR overexpression is mediated in part by a copy number increase of the EGFR gene (Figure 2A) . The outer circles of the circus plot show an alignment of the 22 autosomes in the 4 patients. Most variation is within chromosomes 7 (which contains EGFR) and 10 (which contains PTEN). The inner circles show a detailed view of the two chromosomes, 7 and 10, showing a clear EGFR amplification in all patients. To further evaluate EGFR amplification in these patients, the EGFR copy number from tumour DNA in each case was assessed by quantitative PCR and compared with that of constitutional DNA from circulating lymphocytes. PCR primers were designed to selectively detect sequences of EGFR introns 1, 11 and 21, which were then used to quantify the EGFR copy number in tumours of all patients ( Figure 2B ). The average increase in copy number was as low as 3-fold in patient 3 and as high as 33-fold in patient 7. Interestingly, patient 1 showed an approximate 5-fold amplification when tested with probes located within introns 1 and 11 and about a 14-fold increase with probes localised to intron 21. The increase in the overall copy number of this region is consistent with a tandem duplication of the EGFR kinase domain that has been detected by analysis of in silico data ( Figure 3C ).
Separate mechanisms lead to EGFR overexpression
Analysis of tumours in which EGFR is overexpressed showed that EGFR overexpression is mediated in part by EGFR gene amplification in conjunction with other mechanisms. In an effort to improve clarity and increase simplicity, only those variants that provided clear visual evidence in IGV or were confirmed using PCR and/or Sanger sequencing are included in the Circos diagrams. These include: Tandem duplication of the EGFR kinase domain. DNA amplification that contains all or part of the EGFR gene is the most common mechanism leading to EGFR overexpression. In patient 1 (Figure 3 ), for instance, EGFR is contained within a megabase amplicon on chromosome 7 that has undergone a 4-fold amplification (Figures 2A and 3A) . Closer analysis of in silico data revealed that the EGFR gene had also undergone an intragenic tandem duplication of the kinase domain ( Figure 3A and C and Supplementary Figure S1 , available at Mutagenesis Online). Gene amplification and tandem duplication of the kinase domain was confirmed by Sanger sequencing of EGFR cDNA (data not shown). In addition, PTEN, a negative regulator of EGFR signalling through inhibition of the PI3K pathway (43, 44) (Figure 2A ) and CDKN2A (Supplementary Figure S2 , available at Mutagenesis Online) were deleted in this patient.
Loss of an EGFR repressor. Patient 3 had the lowest increase in copy number, attributable predominantly to chromosome 7 copy number variability. It is unlikely that this modest copy number increase alone is sufficient to account for the increased expression/activation of the EGFR pathway. Analysis of the in silico sequence data of tumour DNA from patient 3 revealed a two megabase deletion on chromosome 1p36 ( Figure 4A and B) that includes the mir34a, which acts as a tumour suppressor by moderating the expression of EGFR and a subset of cell-cycle proteins (45) and also the MIG-6 gene, alternatively designated ERRFI1, RALT or gene 33 (46) (47) (48) (49) (50) . Deletion of MIG-6 is of particular interest since the encoded MIG-6 protein binds to EGFR and regulates its level of abundance (46, (50) (51) (52) .
Constitutive ligand-independent EGFR activity. The GBM tumour from patient 7 displayed a common EGFR variant designated EGFRvIII ( Figure 5 ). In this variant, exons 2 through 7 are deleted as an intragenic in-frame event ( Figure 5B and Supplementary Figure S3 , available at Mutagenesis Online), possibly due to a deletion mediated by Alu sequences (53) . The resultant product is an abnormal isoform that acts as a ligandindependent receptor that is constitutively active and oncogenic (54, 55) . Furthermore, it is highly stable due to altered internalisation and degradation (55) . Like the other tumours described here, EGFR is over-abundant and highly activated, based on IHC for EGFR and its downstream effectors (Figure 1 ).
Overexpression through loss of an ubiquitin docking site. The tumour from patient 8 is a GBM which contains a different intragenic deletion near the 3′ end of the EGFR coding region, resulting in loss of amino acid residues encoded by exons 25 through 27 close to the carboxyl end of the protein ( Figure 6 ). Since this deletion generates an in-frame termination codon, the mutant gene encodes a protein that is truncated at its carboxyl-terminus end. The truncation results in the loss of an autophosphorylation domain and, perhaps more importantly, loss of a tyrosine at position 1045 that plays a key role in binding the c-Cbl ubiquitin ligase. Thus, the truncation is predicted to result in a lack of EGFR ubiquitinylation and consequent proteasome-mediated degradation (56) , resulting in overexpression of this mutant EGFR protein consistent with the EGFR IHC described in Figure 1 . Additionally, Breakdancer calls in this patient revealed that the amplicon that contains EGFR is joined with another small, co-amplified segment ~5 mb upstream of the gene.
Given that each of the four GBMs examined overexpressed EGFR based on IHC, it was important to ensure that there were no lesions in EGFR, other than those described, that would account for the elevated level of the protein. To that end, tumour RNA was isolated and reverse transcribed into cDNA. Four overlapping segments of the EGFR cDNA were directly amplified by PCR and subjected to Sanger sequencing. In no case was there an additional insertion, deletion or non-synonymous missense mutation within the EGFR coding sequence (data not shown).
Discussion
The EGFR gene is mutated or amplified in the majority of brain tumours making it an obvious therapeutic target. EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib have demonstrated a significant in vivo efficacy but a very limited activity in patients diagnosed with GBM (57) . Characterisation of mutations and structural variants that occur with EGFR amplification may provide insight into mechanisms that result in resistance to EGFR-targeting therapies. For instance, EGFR amplification concomitant with activation of a known proliferation effector gives insight into mechanisms that a cell uses to continue to grow and divide in a non-EGFRdependent manner. In addition, this understanding can lead to the identification of potential therapeutic targets in EGFR amplified tumours other than EGFR itself.
One such potential target that has emerged from analysis of our data is the loss of mir34a in patient 3. Restoring mir34a function in the tumour of this patient may inactivate the EGFR pathway and restore p53 function. Indeed, ectopic expression of miR-34a has been shown to induce apoptosis, senescence, cell cycle arrest and to inhibit cell migration and invasion (45, 58) .
In contrast to indirect targeting of EGFR, at least one subset of tumours may benefit from direct targeting of EGFR. The GBM from patient 8 that carries the C-terminal EGFR deletion appears to have an otherwise very stable genome since no other major deletions, translocations or variations in copy number were detected. This apparently stable genome suggests that the tumour may rely predominantly, or exclusively, on the EGFR pathway for its abnormal proliferation. Should this be the case, EGFR inhibitors might be sufficient as single agents in effectively treating the tumour. Stratification of patients based on this deletion may identify a subset of patients that could benefit from EGFR inhibitors. Of the 17 tumours examined to date, 3 harbour similar 3′ EGFR deletions.
Similarly, identifying patients that carry the EGFRvIII deletion will help identify patients that can benefit from EGFRvIIIspecific therapies. Those currently in clinical trials include the peptide-based immunotherapy vaccine (CDX-110) or drugantibody-based therapies (AMG-595). Interestingly these therapies can demonstrate an antitumour effect that is independent to the EGFR oncogenic addiction. Preliminary clinical trials (phase 2 studies) with CDX-110 seems to significantly improve overall survival in EGFRvIII positive tumours, independently of the level of expression of EGFR or other mechanisms involved in its regulation.
Our analyses have described multiple mechanisms whereby EGFR is overexpressed in four GBM tumours. The fact that all of these tumours harboured different EGFR variants, and that our in silico and in vitro analysis correctly identified each of these variants, indicates that our pipeline is able to detect specific variants with considerable accuracy. Indeed, the application of the bioinformatic pipeline often was instrumental in the interpretation of our in vitro results.
These findings from a small GBM cohort highlight the potential benefit of implementing NGS in the management of cancer in general and GBM in particular. Indeed, data generated from the complete molecular profiling of the cancer genome can be used for accurate molecular diagnosis and classification of cancer subtypes. Such data can also be exploited to predict individual prognosis and likely treatment response, which is currently based on probabilistic measures derived from the general population. Finally, it is believed that NGS provides a faster, less invasive but more clinically useful tool for diagnostics, treatment monitoring and personalised detection of recurrence.
Supplementary data
Supplementary Figures 1-4 are available at Mutagenesis Online.
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